A Comprehensive Clinical Description of Pediatric SARS-CoV-2 Infection in Western Pennsylvania

INTRODUCTION

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a fatal cause of pneumonia and was quickly recognized as a potentially fatal multisystemic illness termed coronavirus disease 19 (COVID-19)¹ It has since caused a pandemic of historic proportions. The first confirmed case of SARS-CoV-2 in Allegheny County, in Western Pennsylvania (PA), was on March 11, 2020² While there have been reports on the course of acute COVID-19 in pediatric patients in multiple countries^3–6 as well as studies detailing multisystem inflammatory syndrome in children (MIS-C)^7–10 data on pediatric presentation and severity are still limited. Few published reports of COVID-19 include a comprehensive description of pediatric clinical presentation in the United States (US). Most pediatric studies¹¹are case reports or series of relatively few patients, often inpatients, with those with over 100 patients reporting numbers of children infected in a region, but not specifically describing their clinical characteristics and disease course.¹¹ Many existing studies do not contain child-specific symptom information, often as a result of utilizing ICD code-based retrospective review, and metrics such as underlying medical conditions and hospitalization information are limited.^6,12,13 In addition, Western PA is representative of a phenomenon seen during the early days of the pandemic, with transition to a model of healthcare delivery utilizing more telehealth and fewer in-person visits¹⁴ leading to differences in presentation and management of pediatric patients.¹⁴

From the onset of the pandemic in the region, we created a Pediatric COVID-19 Registry, seeking to characterize the burden of pediatric disease through a collaboration between the University of Pittsburgh Medical Center Children’s Hospital of Pittsburgh (CHP) and the affiliated primary care network, Children’s Community Pediatrics (CCP). CHP is a 315-bed quaternary pediatric care center and admitting hospital that serves a large catchment area, including Western PA, West Virginia, Eastern Ohio, and Western New York. With over 50 locations, CCP is the largest pediatric and adolescent primary care network in Western and Central Pennsylvania. CCP provides care in the Pittsburgh metropolitan area located in Allegheny County, and also in 15 surrounding counties, servicing over 250,000 patients each year. We included all patients receiving care at these facilities who had a confirmed infection with SARS-CoV-2. We then performed a registry-based retrospective chart review to characterize COVID-19 presentation, course of illness, patterns of healthcare utilization, and short-term outcomes.

METHODS

RESULTS

From March 11 through August 20, 2020, there were 955 confirmed pediatric cases (age 0-19) of SARS-CoV-2 in Allegheny County, PA, the most populous county in Western PA²; 296 (31.0%) of them were included in our registry. During that time, the PA Department of Health (DOH) reported 123,364 total cases in the state, including 10,011 (8.1%) in the 0-19 age group¹⁶ Counties represented in our registry reported 18,566 total cases during the study period, or 15.0% of the statewide case burden. While several counties do not report age-specific numbers, based on those data we estimate approximately 1,503 pediatric patients in the region during the study period; our registry contains 424 (28.2% of the estimated regional total) and reflects the numbers of pediatric confirmed infections by date (Figure 1A). Because most pediatric hospital admissions in the region occur at CHP, our cohort likely includes most hospitalized pediatric cases. Figure 1B shows the case distribution by zip code in the Pittsburgh metropolitan area. The distribution of pediatric cases in the registry (Figures 1D) mirrors that of total RT-PCR confirmed cases reported by the PA DOH (Figure 1C).

• Download figure
• Open in new tab

Figure 1: Pediatric COVID-19 cases over time and by geographic location

(A) Allegheny County Health Department (ACHD) total pediatric cases (black) and Registry cases (blue). (B) Pediatric Registry cases by zip code in the Pittsburgh Metropolitan Statistical Area. (C) PA total (adult and pediatric) cases by county. D) Pediatric Registry cases by county, mirroring the distribution of total cases shown in C.

Demographics and presentation to care

All but three cases in the cohort presented with acute disease (99.3%), while remaining cases presented with MIS-C (0.7%). The mean (SD) age of COVID-19 cases was 12.5 (7.1) years, with a median [IQR] of 15.5 [5.9-18.4] and a range of 7 weeks to 21.9 years (Table 1, Figure 2); 52.6% of cases were male. In the cohort, 67.2% of cases identified as white, 24.5% as Black, 3.5% as Asian, and ∼5.2% as other or not reported; six cases (1.4%) identified as Hispanic/Latino. Thirty-seven percent of cases reported a preexisting condition; the most common were asthma (10.6%), neurologic conditions (3.8%), allergic rhinitis (3.5%), cardiac conditions (3.1%), obesity (1.4%), and diabetes (0.9%) (Table 1, Supplementary Table 1). For most cases, initial contact with a healthcare provider was either through telehealth visit (45.0%) or phone call to their PCP (26.2%), reflecting the rapid change in practice as a response to the pandemic in our area (Table 2). The CHP Emergency Department cared for 19.8% of cases, while 3.3% of cases were identified via CHP preprocedural screening, which began in May 2020.

View this table:

• View inline
• View popup
• Download powerpoint

Table 1: Registry Cohort Characteristics

View this table:

• View inline
• View popup

Table 2: Exposure and Diagnosis

• Download figure
• Open in new tab

Figure 2: Age distribution, exposures, and symptoms by age group

(A) Histogram of age distribution in pediatric COVID-19 cases. (B) Distribution of exposures by age group. (C) Symptom heatmap by age group, for acute COVID-19 and MIS-C.

Exposure and testing

Most cases in the cohort tested positive for SARS-CoV-2 via RT-PCR on a nasopharyngeal sample, and two cases of MIS-C had positive IgG serology (Table 2). Most testing was performed at the UPMC drive-through testing facility (61.3%), followed by testing at CHP (20.5%). Seventeen cases (4.0%) had previously tested negative for SARS-CoV-2, including four hospitalized patients: two with MIS-C, one with cystic fibrosis, and one who tested negative prior to a neurosurgical procedure, then presented with acute COVID-19 one week later.

Most children had at least one known exposure to another person with COVID-19 (65.3%) (Table 2). The most common exposures were other family members at home (50.9%), peers (25.9%), and visiting relatives (19.1%). Exposure varied by age group, with the youngest group (0-2 years) most likely being exposed at home (69.8%), by other family (27.0%), or via childcare (1.6%); and the young adults (18-21 years) exposed by peers (57.4%), at work (11.8%), or at bars/restaurants (1.5%) (Figure 2B). Forty-one patients (9.7%) reported travel within the two weeks prior to presentation of illness, mostly to locations requiring air travel.

For cases with available dates of exposure, on average (SD), there were 4 (4.6) days from exposure to symptom onset, 2.5 (3.1) days from symptom onset to health care presentation, and 1.7 (3.2) days from presentation to testing; total interval from symptom onset to testing was 3.7 (3.8) days (Table 2, Figure 3 A-D).

• Download figure
• Open in new tab

Figure 3: Histogram of timeline distribution

Histogram of days from exposure to symptoms (A), from symptom onset to initial presentation to care (B), from presentation to care to test (C) and from symptom onset to test (D). In (A), the patients with greater than 30 days since exposure presented with MIS-C.

DISCUSSION

In this report, we provide a comprehensive clinical description of pediatric COVID-19 in Western PA, a region with a low to moderate case burden. We describe clinical presentation and healthcare utilization for the breadth of pediatric disease, ranging from asymptomatic patients identified on preprocedural screening to critically ill patients with the presentation of either acute COVID-19 or MIS-C. Due to the market capture of the participating institutions, we are able to provide a sampling of cases that likely mirrors all pediatric disease in the area, with a bias toward inclusion of children who require hospitalization or intensive care. These cases span the date range of March to August 2020, a period in which all schools were closed to in-person learning in our area.

The demographics of our cohort mirror some national trends, demonstrating that Black and Hispanic adults ^17,18,19 and children ^20,21 are more likely to be infected with or have worse outcomes from COVID-19. According to the most recent available census data²² the largest ethnic groups in Allegheny County, PA, are non-Hispanic whites (79.9%) followed by non-Hispanic Blacks (13.4%). While our registry encompasses an entire region of the state and not solely this county, Black patients are overrepresented among infected children (24.5% of patients in the registry). While the total number is small, all individuals who presented with MIS-C were from minority groups, which also aligns with prior reports^23,24. Racial/ethnic differences in hospitalization risk remained significant after accounting for age, sex, the presence of chronic conditions, and the time lapse between symptom onset and COVID-19 testing.

This study also highlights, as is true for many pediatric conditions, that symptoms of SARS-CoV-2 infection vary with the age of the child. The youngest children were more likely to present with fever, cough, and rhinorrhea than older children, who more frequently presented with a syndrome of more numerous symptoms that may not include fever. Evaluating children, particularly in the outpatient setting, through this lens can be beneficial in recognizing potential SARS-CoV-2 infection, particularly as it presents with symptoms similar to other respiratory viral pathogens²⁵.

Based on the data in our area, we estimate a prevalence of MIS-C of approximately 2.0 per 1,000 SARS-CoV-2 pediatric infections. However, this is likely an overestimate, since children can have asymptomatic disease (up to 2.2% of well-children based on all comers for pre-procedure screening²⁶), and thus symptom-based screening likely excludes some infected patients. In addition, our center receives transfers for more severe disease in the region, including MIS-C. Other estimates of MIS-C prevalence have ranged from a nationwide rate of 2.0 per 1,000 (694/355,123)²⁷ to the PA statewide rate of 4.3 per 1,000 (43/10,011)¹⁶.

Another important observation during this study is the rapid rise in the rate of telehealth appointments. While CCP did not routinely use telemedicine prior to this pandemic, they rapidly adapted to being able to provide care and counseling (especially for patients with respiratory symptoms), monitor patients, and arrange for SARS-CoV-2 testing at an off-site drive-through testing facility to decrease exposure risk in their offices. Several subspecialty disciplines also moved the majority of routine outpatient encounters to virtual visits within days of the first case detected in the region. Telehealth will continue to play an important role in pediatric healthcare delivery as we move into the winter respiratory illness season, when SARS-CoV-2 will be circulating in addition to other typical winter viruses such as influenza and RSV. This will also be crucial given the additional burden placed on outpatient healthcare providers who are being asked to provide clearance for ill children to return to school in the era of COVID-19.

This study has several strengths. Our registry is based on information abstracted directly from the EHR by providers involved in the care of these children, which provides more detailed and accurate information than reports based on ICD-10 codes or claims data. We were therefore able to break down patterns by age group. The registry cohort represents a wide range of SARS-CoV-2 pediatric clinical presentations outside of a pandemic “hotspot”; disease severity is thus less likely affected by strain on the system or difficulties accessing care. Our results advance prior pediatric literature showing higher risk of SARS-CoV-2 infection in minority children to show that these children are also at higher risk of severe disease, as has been reported in adults. At the same time, we must acknowledge study limitations. First, given the scope of practice at our referral center, we cannot rule out bias towards more severe disease; however, most cases were detected and followed as outpatients at CCP. Second, the current report does not yet include long-term patient outcomes and, thus, these data provide a limited understanding of patient recovery or long-term sequelae. However, this real-time registry will allow for additional follow-up on these metrics. We can use this tool to measure how dynamics of the outbreak in the pediatric population change with added factors in the coming months, including changes in child behavior with the school year, the respiratory virus season, and hopefully the eventual introduction of vaccines.

In summary, this report provides a comprehensive overview of the breadth of presentation of pediatric infection with SARS-CoV-2 in a single geographic area. In general, pediatric patients tolerate this infection well, with only a small proportion (∼5%) requiring hospital admission, and even fewer (∼1.2%) presenting with critical illness. Large, multicenter collaborative efforts will be crucial to better understand factors associated with severe pediatric SARS-CoV-2 disease, particularly in racial and ethnic minorities at higher risk.

Funding

This work was supported in part by the Clinical and Translational Science Institute, University of Pittsburgh supported by the National Institutes of Health/National Center for Advancing Translational Sciences [grant number UL1-TR-001857], the Pediatric Infectious Disease Society and St. Jude Children’s Research Hospital Fellowship Program in Basic and Translational Research to MCF, the National Institutes of Health/ National Heart, Lung, and Blood Institute [grant number T32-HL129949] to KMG, the Pediatric Scientist Development Program (PSDP) sponsored by the Association of Medical School Pediatric Department Chairs (AMSPDC) funded by the National Institutes of Health/ National Institute of Child Health and Human Development [grant K12HD000850-34] to GJR, and the National Institute of Health/National Heart, Lung, and Blood Institute [grant number R01-HL149693] to EF. The authors do not have any conflicts of interest to declare related to this work.